PTC Therapeutics (NASDAQ:PTCT) Stock Gets Price Target Boost from Royal Bank Of Canada

PTC Therapeutics (NASDAQ:PTCT) had its target price increased by analysts at Royal Bank Of Canada from $75.00 to $77.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s target price suggests a potential upside of 23.40% from the company’s current price.

PTCT has been the topic of several other research reports. Leerink Partners began coverage on shares of PTC Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $98.00 price objective on the stock. Wells Fargo & Company lifted their price target on shares of PTC Therapeutics from $106.00 to $109.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Cantor Fitzgerald boosted their price objective on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a report on Tuesday, September 22nd. Morgan Stanley boosted their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.29.

PTC Therapeutics Stock Performance

Shares of PTCT traded down $2.06 during mid-day trading on Friday, reaching $62.40. 963,860 shares of the company were exchanged, compared to its average volume of 1,345,500. The business has a 50 day simple moving average of $65.57 and a two-hundred day simple moving average of $70.87. The stock has a market capitalization of $5.21 billion, a PE ratio of -107.58, a PEG ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a 52 week low of $58.80 and a 52 week high of $90.87.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million for the quarter, compared to the consensus estimate of $306.43 million. The business’s revenue was up 69.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share. On average, analysts predict that PTC Therapeutics will post 1.19 EPS for the current year.

Insider Activity at PTC Therapeutics

In other news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total value of $781,920.00. Following the completion of the transaction, the director directly owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president owned 105,272 shares of the company’s stock, valued at $6,754,251.52. This trade represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 77,370 shares of company stock worth $5,322,261. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of PTC Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in PTC Therapeutics in the second quarter worth $1,139,089,000. Jupiter Topco LLC bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at about $590,182,000. Janus Henderson Group PLC raised its position in shares of PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock worth $489,997,000 after acquiring an additional 2,342,101 shares in the last quarter. William Blair Investment Management LLC purchased a new position in PTC Therapeutics during the 2nd quarter valued at about $140,520,000. Finally, Bank of America Corp DE bought a new stake in shares of PTC Therapeutics in the 2nd quarter worth approximately $118,462,000.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year and above the roughly $306 million consensus estimate. Product revenue was $276 million, led by Sephience (sepiapterin), which generated $182 million as U.S. adoption and international expansion continued. PTC Therapeutics Third-Quarter Results
• Positive Sentiment: Management raised its 2026 outlook, now expecting total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. The upgrade signals confidence in Sephience’s commercial momentum and the broader product portfolio. PTC Therapeutics Raises 2026 Outlook
• Positive Sentiment: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026. The deal adds a potential late-stage growth asset, although regulatory and development execution remain important risks. PTC Corporate Update
• Negative Sentiment: Reported profitability was mixed. PTC posted a GAAP loss of $0.62 per share, well below the consensus estimate for $0.14 of earnings, even though an adjusted earnings measure cited by Zacks was $0.61 per share and above estimates. The conflicting measures may have contributed to investor caution. PTC Swings to Third-Quarter Loss
• Neutral Sentiment: The earnings call focused on Sephience’s launch trajectory, global expansion, the ST-920 acquisition and the updated 2026 outlook. Investors will likely monitor whether revenue growth translates into sustainable earnings and cash flow. PTC Q3 2026 Earnings Call Transcript

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.